Biodexa Pharmaceuticals plc cash flow statement

In fiscal 2023, Biodexa Pharmaceuticals plc's operations generated −$8.5m of cash; it spent $32,344 on capital projects, leaving free cash flow of −$8.5m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Biodexa Pharmaceuticals plc: cash flow statement, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023
Cash from operations	−19	−18	−17	−18	−8	−12	−8	−9	−8
Depreciation and amortisation	−0	0	0	0	—	—	—	—	—
Stock-based pay	0	0	1	−0	−0	−1	0	0	0
Capital spending	1	2	1	0	0	0	0	0	0
Free cash flow	−20	−20	−18	−18	−9	−12	−9	−9	−9
Free cash flow after stock pay	−21	−20	−18	−18	−9	−12	−9	−9	−9

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Biodexa Pharmaceuticals plc's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biodexa Pharmaceuticals plc.